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DOI 10.1016/j.ccr.2011.09.003SUMMARYExtensive crosstalk among ErbB/HER receptors suggests that blocking signaling from more than one family
member may be essential to effectively treat cancer and limit drug resistance. We generated a conventional
IgG molecule MEHD7945A with dual HER3/EGFR specificity by phage display engineering and used struc-
tural and mutational studies to understand how a single antigen recognition surface binds two epitopes
with high affinity. As a human IgG1, MEHD7945A exhibited dual action by inhibiting EGFR- and HER3-medi-
ated signaling in vitro and in vivo and the ability to engage immune effector functions. Compared with mono-
specific anti-HER antibodies, MEHD7945A was more broadly efficacious in multiple tumor models, showing
that combined inhibition of EGFR and HER3 with a single antibody is beneficial.INTRODUCTION
Deregulation of the epidermal growth factor receptor family
plays an important role in tumorigenesis (Hynes andMacDonald,
2009), and targeted agents directed against two members of
the HER/ErbB family, epidermal growth factor receptor (EGFR/
HER1) and HER2/ErbB2, are used in the treatment of cancer
(Ciardiello and Tortora, 2008; Moasser, 2007). Mutation and/or
overexpression of these receptors produce aberrant proliferative
signals arising from the tyrosine kinase activity of their intracel-
lular domains. There is promiscuous association among family
members and each receptor activates a distinct but overlapping
repertoire of downstream pathway components (Jones et al.,Significance
Alterations in expression or activation of HER/ErbB family mem
cific antibodies targeting individual ErbB/HER receptors. A tw
ErbB3 and inhibits receptor function. Here, we demonstrate su
specific HER antibodies. The activity profile of the dual-specific
targeting both receptors and supports its clinical evaluation in s
role in tumorigenesis.
472 Cancer Cell 20, 472–486, October 18, 2011 ª2011 Elsevier Inc.2006; Olayioye et al., 2000) and multiple receptors can con-
tribute to tumor growth.
To date, HER3 is not reported to undergo oncogenic activation
as a result of mutation or amplification. However, during the last
decade unique structural aspects of HER3 emerged which
produced insights and questions regarding the receptor’s func-
tion in normal tissue and hyperproliferative conditions such as
cancer. The cognate ligand for HER3 is heregulin (HRG; also
called neu differentiation factor) (Carraway et al., 1994). In the
absence of an appropriate coreceptor, HRG binds to HER3
with relatively low affinity. In the presence of another HER
family member, the low-affinity HRG binding site is converted
to a high-affinity site by the formation of a heterodimeric complexbers can limit the efficacy or lead to resistance to monospe-
o-in-one antibody, MEHD7945A, binds to EGFR and HER3/
periority of the dual-specific EGFR/HER3 antibody to mono-
EGFR/HER3 antibody validates the utility of simultaneously
ettings where HER/ErbB signaling is thought to play a major
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domain exists in a closed conformation and undergoes an
impressive conformational change in the presence of ligand
that allows for the formation of a two domain ligand binding
site and the exposure of a receptor dimerization arm (Cho and
Leahy, 2002). Because it is a pseudokinase (Jura et al., 2009b),
HER3 was initially, and simplistically, regarded as being merely
a substrate for HER/ErbB transactivation. Recent, elegant
studies further elaborate the HER3 kinase domain as an allo-
steric activator for its enzymatically competent counterparts
(Jura et al., 2009a). HER3 is further differentiated from other
HER family members, and for that matter other receptor tyrosine
kinases, by the presence of six tyrosines in the C-terminal tail
that when phosphorylated directly recruit the p85 subunit PI3
kinase (Prigent andGullick, 1994; Soltoff et al., 1994). As a conse-
quence, the HER3-PI3 kinase node is emerging as a potential
target for anticancer therapy (Schoeberl et al., 2010).
The therapeuticEGFRantibodiescetuximabandpanitumumab
antagonize EGFR signaling by blocking ligand binding. These
antibodies showmarginal objective responses in advanced colo-
rectal cancer patients when used as single agents. Randomized
trials of EGFR antibodies combined with chemotherapy showed
a statistically significant, albeit modest, increase in progression
free survival versus chemotherapy alone, especially in tumors
that are wild-type for K-ras (Grothey, 2010).
Themost impressive single agent activity of EGFR antagonists
is observed in non-small cell lung cancer (NSCLC) patients
whose tumors harbor somatic kinase domain mutations and
are treated with erlotinib or gefitinib (Lynch et al., 2004; Paez
et al., 2004). In contrast, the clinical benefit in patients with
wild-type EGFR NSCLC is considerably diminished. Preclinical
studies report a strong association between sensitivity to gefiti-
nib in NSCLC cell lines and the inactivation of HER3 (Engelman
et al., 2005). Moreover, this observation was extended to a panel
of colorectal and pancreatic cancer cell lines, where erlotinib
antiproliferative activity was again correlated with inhibition of
HER3 phosphorylation (Buck et al., 2006). These findings raise
the possibility that in the absence of EGFR kinase domain muta-
tions, optimal clinical benefit of anti-EGFR requires that HER3 is
also inhibited.
Antibodies are valued as therapeutics for their high affinity and
exquisite specificity. To further build on this clinical success,
a wide array of proteins with antibody-like binding properties is
now available. For example, the generation of many bispecific
platforms, which vary from small diabody formats to tetrameric
structures (Chames and Baty, 2009). Antibodies engineered
with more than one binding specificity enable multiple antigens
to be targeted, for example, EGFR and the T cell receptor (Lutter-
buese et al., 2010). Typically, these bitargeting agents are con-
structed by linking two distinct antigen-binding modules into
one molecule, each module being able to bind only one antigen.
We reasoned that a combination of an antibody directed against
EGFR and HER3 might be more effective for EGFR-driven
cancers than existing antibody therapies. Our approach was to
double the function of a single antibody binding site creating
a surface that specifically binds two, and only two, target anti-
gens with high affinity. This notion is a stark violation of a cardinal
property of natural antibodies, that one antibody recognizes one,
and only one antigen. The first such two-in-one antibodyCdescribed binds VEGF and HER2 (Bostrom et al., 2009). Our
aim in the current work was to generate a two-in-one antibody
directed against HER3 and EGFR.RESULTS
Complete Inhibition of MAPK and AKT Signaling
Is Achieved Only When EGFR and HER3 Are Blocked
Simultaneously
The two major downstream signaling pathways in the HER/ErbB
family activated in response to ligand stimulation are the Ras/
MAPK and the phosphatidylinositol 3-kinase (PI3K)/AKT
pathway. To learn if the blockade of either EGFR or HER3 alone
is sufficient to inhibit both pathways, we evaluated pathway
modulation using ligands and antireceptor antibodies. We chose
two cell lines that express similar levels of HER3 but differ greatly
in EGFR expression to better reflect the variations of receptor
levels seen in tumor cells: A431 cells (1.2 3 106 EGFR per
cell) and BxPC3 cells (6.3 3 104 EGFR per cell) (Lynch and
Yang, 2002). Treatment with the HER3 ligand heregulin (HRG)
induced robust phosphorylation of HER3 and AKT in both cell
lines but had no effect on EGFR phosphorylation and only
marginal effect on ERK1/2 phosphorylation (Figure 1, lane 2).
The phosphorylation of HER3 and AKT was ablated when cells
were pretreated with an anti-HER3 antibody (lane 3) but were
unchanged when treated with cetuximab (lane 4). In contrast,
treatment with the EGFR ligand TGF-a resulted in strong phos-
phorylation of EGFR and ERK1/2 but had no or marginal effect
on HER3 or AKT phosphorylation (lane 5). Pretreatment with ce-
tuximab effectively blocked TGF-a-induced phosphorylation of
EGFR and ERK1/2 (lane 7), whereas anti-HER3 had no effect
(lane 6). Importantly, in the presence of both ligands robust phos-
phorylation of HER3, EGFR, AKT and ERK1/2 occurred (lane 8)
and only pretreatment with cetuximab plus anti-HER3 com-
pletely prevented receptor phosphorylation and downstream
signaling in both cell lines (lane 11). These findings suggest
that, in a ligand-rich tumor environment, effective shutdown of
the HER axis would require ablation of both EGFR- and HER3-
driven signaling.Generation of a Ligand Blocking Anti-EGFR Monoclonal
Antibody
To explore the therapeutic potential of a dual-action antibody
that can block both signaling pathways, we sought to generate
an antibody that would recognize and inhibit EGFR as well as
HER3. We first isolated an anti-EGFR antibody, D1, from a
phage-displayed Fab library based on its ability to block TGF-a
binding to EGFR and then improved D1 to the high-affinity
variant D1.5 (Kd = 0.4 nM) by affinity maturation (Lee et al.,
2006; Figure 2A). D1.5 potently inhibited 125I-EGF binding to
EGFR (Figure S1). The ability of D1.5 to block ligand binding
translated into potent inhibition of TGF-a-stimulated phosphory-
lation of EGFR, downstream signaling, and cell proliferation of
EGFR-NR6 cells. Further, D1.5 demonstrated potent antitumor
activity in the EGFR amplified A431 xenograft model that is highly
sensitive to anti-EGFR therapeutics (Figure 2B and Figure S1).
The antitumor activity of D1.5 was comparable to the activity
seen with cetuximab (Kd = 0.7 nM) (Table S1).ancer Cell 20, 472–486, October 18, 2011 ª2011 Elsevier Inc. 473
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Figure 1. Combination of EGFR and HER3 Antibodies Is Necessary to Abolish Ligand Induced Activation of PI3K/AKT and ERK Signaling
A431 and BxPC3 cells were treated for 3 hr with indicated antibodies (10 mg/ml) and stimulated with HRG (0.5 nM), TGF-a (0.5 nM), or combination of both ligands
for 10 min. Cell lysates were immunoblotted to detect pHER3 (Tyr1289), pAKT (Ser473), pERK1/2 (Thr202/Tyr204), pEGFR (Tyr1068), and tubulin.
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After establishing D1.5 as an effective EGFR inhibitor, we sought
to add anti-HER3 activity. Since D1.5 was isolated from an anti-
body library with diversity restricted to the heavy-chain CDRs,
we expected its important anti-EGFR residues to be in the heavy
chain. We constructed a library of D1.5 variants with mutations in
the light-chain CDRs and were able to identify clones that bound
HER3 while maintaining binding to EGFR. These clones, e.g.,
D1.5-100, not only bound to both receptors but also blocked
ligand binding to EGFR and HER3, albeit with much reduced
affinity for EGFR (EC50 100 nM) (Figure 2A).
To demonstrate antiproliferative activity of these dual-specific
antibodies, we reformatted and expressed several phage clones
as human IgG1 proteins. To evaluate HER3 inhibition, we chose
a breast cancer cell line, MDA-MB-175, that secretes HRG and
as a result activates HER3 in an autocrine manner (Schaefer
et al., 1997). We used EGFR-NR6 cells as described above
to verify the antagonism of EGFR. As expected, D1.5 potently
inhibited ligand-induced growth of EGFR-NR6 cells in a dose-
dependent manner but had no effect on the growth of MDA-
MB-175 cells (Figure 2B). The dual-specific antibodies, however,
were able to inhibit EGFR- and HER3-mediated proliferation in
the two cell lines. D1.5-100, which differs from D1.5 by only
five amino acid substitutions in the light chain (Figure 2A),
potently inhibited the growth of MDA-MB-175 cells, demon-
strating that binding to HER3 translated into potent in vitro
activity. However, the low affinity of D1.5-100 for EGFR led to
inhibition of TGF-a-driven growth of EGFR-NR6 cells only at
high concentrations (Figure 2B).
To improve the dual affinity of D1.5-100, we first assessed the
energetic importance of the CDR residues necessary for binding474 Cancer Cell 20, 472–486, October 18, 2011 ª2011 Elsevier Inc.to EGFR and HER3 using alanine and homolog mutagenesis
scanning (Supplemental Experimental Procedures). The analysis
revealed that, as expected, heavy-chain CDR residues are
dominant in EGFR binding. In contrast, HER3 binding required
residues from both light-chain and heavy-chain CDRs (Table
S2). By stringent affinity-based selection from the homolog
libraries, we identified many variants with improved affinity. We
focused on one Fab, designated DL11f (termed MEHD7945A
when reformatted as IgG), which exhibited improved binding
affinities for both EGFR and HER3 (Kd 1.9 and 0.4 nM, respec-
tively) (Figure 2A, Table S1). DL11f has twelve amino acid substi-
tutions compared with D1.5. The enhanced binding affinities of
DL11f for EGFR and HER3 translated into increased antiprolifer-
ative activity in EGFR-NR6 and MDA-MB-175 cells (Figure 2B).
EGFR and HER3 Compete for Binding to MEHD7945A
To assess specificity, we examined the binding of DL11f toward
a panel of proteins using an ELISA assay. As expected, DL11f
bound to human EGFR and human HER3. Interestingly, DL11f
cross-reacted with murine EGFR but not with murine HER3;
both orthologs are highly homologous to the human counterpart.
DL11f did not show any detectable binding to HER2 or HER4
(data not shown).
Typically, bitargeting agents are constructed by linking two
distinct antigen-binding modules, each module being able to
bind to only one antigen. In contrast, in MEHD7945A, each
module (Fab) can bind either of two antigens, thus having the
potential to elicit enhanced binding affinity from an avidity effect.
To confirm that each of the two identical Fabs of MEHD7945A
can bind either EGFR or HER3, we performed a competitive
binding assay. MEHD7945A binding to immobilized HER3-ECD
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Figure 2. Biochemical Characterization of the Dual-Action Antibodies and Their Monospecific Parents
(A) Sequence alignment of CDRs of D.1, D1.5, D1.5-100, DL11, or DL11f, in the order they were created. Amino acid changes relative to each sequence’s
immediate precursor are highlighted in yellow. Relative affinities of the various Fabs as phage clones or as purified Fab protein were determined by ELISA or SPR,
respectively.
(B) EGR-NR6 cells in the presence of 3 nM TGF-a, or MDA-MB-175 cells were treated with indicated concentrations of D1.5 (blue line), D1.5-100 (gray line),
or MEHD7945A (red line) in the presence of 1% serum containing growth medium. Cell proliferation was measured after 3 days using AlamarBlue staining.
The results are expressed in relative fluorescence units (RFU).
(C)MEHD7945A binding to immobilizedHER3-ECD or EGFR-ECD as indicated in the presence of indicated soluble competitor. 13 = 0.02 mg/ml, 103 = 0.2 mg/ml,
1003 = 2 mg/ml, 10003 = 20 mg/ml. Results expressed as MEHD7945A concentration versus OD.
See also Figure S1 and Tables S1 and S2.
Cancer Cell
Targeting HER3 and EGFR with a Two-in-One Antibody
Cancer Cell 20, 472–486, October 18, 2011 ª2011 Elsevier Inc. 475
Figure 3. Crystal Structure of DL11 in Complex With EGFR-ECD or HER3-ECD
(A) DL11 (surface in pink [light chain] and blue [heavy chain]) binds to EGFR (left, green) and to HER3 (right, orange) at similar regions of domains 3. The magnified
views (boxed) are viewed after aligning EGFR and HER3 domain 3. For EGFR, the full-length version of EGFR ecd found in PDB entry 1YY9 is included for
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amounts of EGFR-ECD. Conversely, MEHD7945A was com-
peted from immobilized EGFR-ECD by soluble HER3-ECD pro-
tein. As expected, given their relative binding constants, higher
concentrations of soluble EGFR-ECD were needed to compete
with binding of MEHD7945A to immobilized HER3-ECD
(Figure 2C).Key Differences in the Way DL11 Binds EGFR and HER3
To learn how a single Fab interacts with two homologous recep-
tors (homology in ECD 45%), we determined crystallographic
structures of DL11 alone (2.85 A˚), in complex with EGFR domain
3 (residues Arg310-Lys514) (1.8 A˚) and in complex with HER3
domains 1–3 (residues Ser1-His513) (3.7 A˚) (Figure 3, Table
S3). DL11 is a variant of DL11f differing by three subtle amino
acid differences (Figure 2A) with indistinguishable binding (Table
S1) and antiproliferative activities (data not shown). DL11 Fabs in
the three structures have no significant differences in their main
chain conformations (Figure S2). The arrangement of the HER3
domains 1–3 in the HER3-DL11 complex is essentially identical
to the ‘‘tethered’’ structure of unliganded HER3 (Cho and Leahy,
2002; Figure 3A).
The sizes of the DL11/receptor interfaces are typical for anti-
body-protein antigen complexes, with the EGFR complex having
800 A˚2 buried on each side, and the HER3 complex having
890 A˚2. The larger interface area in the HER3 complex arises
from the inclusion of twice as much DL11 light-chain surface
as in the EGFR complex (225 versus 100 A˚2) (Figure 3A). This
is consistent with the greater importance of light-chain CDR resi-
dues for HER3 binding (Table S4) and the fact that HER3 binding
was initially acquired using changes in the light chain of D1.5.
The DL11 epitopes are at similar region of domain 3 of the two
receptors but are shifted with respect to each other by 13 A˚
(Figures 3A and 3C). The shift of the structural epitopes is re-
vealed by the distinct sets of main contacts, which are at a
segment of low homology (Figure 3D). Although the epitopes
on the two receptors do not exactly correspond to each other
structurally, there are some common features in the two inter-
faces: both epitopes are generally basic and the antibody
contact regions are generally acidic (Figure S2).
The EGFR epitope of DL11 overlaps with the cetuximab
epitope and they both include ligand-binding residues (Li et al.,
2005, Figure 3B, Figure S2). In addition, both antibodies would
present a steric clash limiting the receptor’s access to the ‘‘un-
tethered’’ conformation that is stabilized by ligand binding (Fig-
ure S2). Such a conformation is implicated in receptor signaling.reference (gray). For HER3, the full-length version of HER3 ecd from PDB entry 1M
1-513 is preserved from the full-length ecd, albeit imperfectly. There are 24 amin
1M6B. These residues adopt a conformation closely similar to that of homologo
(B) DL11 epitopes of aligned EGFR (left) and HER3 (right) domains 3. The surface c
functionally critical, determined by mutagenesis (residues labeled in red) and gray
EGF from the PDB entry 1IVO.
(C) When viewed with superposed antigens (colored as in part A) it is apparent t
by 13 A˚.
(D) Sequence alignment of the DL11 epitope regions on EGFR and HER3. Dots in g
HER3 residues within 4 A˚ of DL11. Murine ortholog and human HER2 sequences
side chain character. Boxed dots indicate functionally important residues colore
See also Figure S2 and Tables S3 and S4.
CAt present, there is no crystal structure reported for HER3 bound
to a ligand, but we presume HER3 ligands bind regions on
domain 1 and domain 3 by analogy to EGFR/ligand structures.
Thus, the DL11f mechanism of action for both EGFR and HER3
is one of ligand blocking and a restriction on ECD conformations.
We next performed alanine scanning of both receptors to
determine the energetic contributions of the residues making
structural contacts (Figure 3B, Figure S2). We found that resi-
dues in the center of the contact regions and their interacting
residues on DL11 are generally important functionally thus cor-
roborating the crystal structures (Figure 3B). The critical impor-
tance of Arg472 and His467 for the HER3 interaction explains
why DL11f does not bind murine HER3 as the two residues are
not conserved in murine HER3, which is otherwise 94% identical
to human HER3 (Figure 3D). Consistent with the polar natures of
the interacting surfaces, the functional data demonstrate the
importance of charged side chains (Figure 3B). However, the
energetic importance of Ile467 and Phe412 for the EGFR interac-
tion suggests that binding is not driven by purely charged or
polar interactions. Overall, the structural and alanine scanning
results demonstrate that the dual-specific DL11 Fab engages
distinct epitopes on the two receptors in a highly specificmanner
by unique use of light- and heavy-chain CDR residues.MEHD7945A Potently Inhibits Receptor
Phosphorylation of EGFR and HER3
We next evaluated the dual activity of MEHD7945A in cell sig-
naling assays. To assess the inhibitory function on HER3, we
chose MCF-7 cells for which HRG treatment potently activates
the HER2/HER3 pathway. Treatment with MEHD7945A prior to
HRG stimulation potently inhibited the phosphorylation of HER3
in a dose-dependent manner, and markedly decreased the
phosphorylation of AKT and ERK1/2 (Figure 4A). MEHD7945A
inhibited phosphorylation of HER3 with an IC50 of 0.05 mg/ml,
phosphorylation of AKT with an IC50 value of 0.19 mg/ml, and
phosphorylation of ERK1/2 with an IC50 value of 1.13 mg/ml.
Treatment with a monospecific antibody against HER3, anti-
HER3, that has comparable binding affinity to HER3 (Table S1)
achieved similar results. Anti-HER3 inhibited phosphorylation
of HER3 with an IC50 of 0.12 mg/ml, phosphorylation of AKT
with an IC50 value of 0.74 mg/ml, and phosphorylation of ERK1/
2 with an IC50 value of 1.83 mg/ml. We pretreated EGFR-NR6
cells with MEHD7945A prior to ligand stimulation and deter-
mined that MEHD7945A inhibited phosphorylation of EGFR
and ERK1/2 with IC50 values of 0.03 and 0.16 mg/ml, respectively
(Figure 4B). The monospecific EGFR antibody cetuximab was6B is included for comparison (gray). The overall domain organization of HER3
o acids (Gly12–Glu36), which are present in our model but were not visible in
us residues in EGFR, HER2, and HER4.
olors are dark blue for the contact surface (4 A˚ cutoff), red for residues that are
elsewhere. For EGFR, a dashed line outlines the contact region (4 A˚ cutoff) for
hat DL11 (pink, represented by Tyr96 from the light chain for clarity) is shifted
reen field denote EGFR residues within 4 A˚ of DL11. Dots in orange field denote
are provided for comparison. Amino acid code letters are colored according to
d red in part (B). Residue numbers appear in gray.
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Figure 4. MEHD7945A Inhibits EGFR and HER2/HER3-Dependent Signaling
(A) MCF-7 cells treated with indicated concentrations of MEHD7945A or anti-HER3were stimulated with 0.5 nMHRG for 10min. Cell lysates were immunoblotted
to detect pHER3 (Tyr1289), pAKT (Ser473), pERK1/2 (Thr202/Tyr204), and total HER3.
(B) EGFR-NR6 cells treated with indicated concentrations of MEHD7945A or cetuximab for 1 hr prior stimulation with 5 nM TGF-a for 10 min. Cell lysates were
subjected to immunoblotting to detect, pERK1/2 (Thr202/Tyr204), total EGFR, and phosphorylated EGFR. Since EGFR-NR6 cells only express EGFR all potential
phosphorylation sites of EGFR were detected using a pTyr antibody.
(C) H1666 cells were treated with increasing concentration of cetuximab (orange line), pertuzumab (purple line), anti-HER3 (blue line), the combination of
cetuximab plus anti-HER3 (gray line) or MEHD7945A (red line) in the presence of HRG (2 nM). Concentrations shown on the x axis reflect the concentration of
the single antibody. Cell proliferation relative to untreated control was measured after 4 days using AlamarBlue staining.
(D) A431 cells were treated with increasing concentrations of cetuximab (orange line), pertuzumab (purple dots), anti-HER3 (blue line), the combination of
cetuximab plus anti-HER3 (gray line) or MEHD7945A (red line). Cell proliferation relative to untreated control was measured after 3 days using AlamarBlue
staining.
See also Figure S3.
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stream signaling molecules, which was likely due to the higher
binding affinity to EGFR (Table S1). Moreover, betacellulin- and
amphiregulin-induced EGFR phosphorylation was also inhibited
by MEHD7945A (Figure S3). MEHD7945A inhibited ERK1/2 and
AKT pathways as potently as the combination of anti-HER3 and
cetuximab in A431 and BxPC3 cells (Figure S3).478 Cancer Cell 20, 472–486, October 18, 2011 ª2011 Elsevier Inc.Having establishedMEHD7945A as a potent inhibitor of ligand
binding (Figure S3) and signaling, we next compared it to mono-
specific antibodies in cell proliferation assays. We first chose
the NSCLC cell line H1666 that expresses EGFR, EGFR
ligands, HER2, and HER3 (Zhou et al., 2006) and responds to
HRG stimulation (Schaefer et al., 2007). For monospecific anti-
HER antibodies, we chose cetuximab as an EGFR inhibitor,
Cancer Cell
Targeting HER3 and EGFR with a Two-in-One Antibodypertuzumab as an HER2 inhibitor (Agus et al., 2002) and anti-
HER3. Cetuximab did not significantly inhibit cell growth but
a dose-dependent decrease of proliferation was seen with either
pertuzumab or anti-HER3 (Figure 4C). The greatest inhibition of
cell growth, however, was achieved with MEHD7945A, suggest-
ing that inhibition of both EGFR and HER3 is more efficacious in
cells where both receptors are prone to activation. Intriguingly,
MEHD7945A potently inhibited cell proliferation at lower anti-
body concentrations compared with the combination of cetuxi-
mab plus anti-HER3. The greater potency may be due to
MEHD7945A’s unique ability to simultaneously engage two
EGFR, two HER3 or one of each receptor on the surface of cells.
We performed similar proliferation assays using A431 cells that
do not require exogenous ligands for growth. MEHD7945A
also inhibited the proliferation of these cells more potently than
cetuximab, pertuzumab, anti-HER3, and also the combination
of cetuximab plus anti-HER3 (Figure 4D). Taken together, these
data demonstrate that MEHD7945A exhibits increased antiproli-
ferative activity compared with monospecific HER antibodies
in vitro.
MEHD7945A Inhibits HER3-Dependent Cell Growth
In Vitro and In Vivo
To identify HER3-driven tumors in which to examine the in vivo
activity of MEHD7945A, we performed an RNAi screen. Knock-
down of receptor expression was confirmed by immunoblotting.
BxPC3, a pancreatic cancer cell line, showed the strongest
growth inhibitory effect upon HER3 silencing. RNAi knockdown
of EGFR also slowed the growth of BxPC3 cells but to a lesser
extent suggesting growth of BxPC3 cells was mainly mediated
by HER3 and only in part by EGFR (Figure 5A).
We next determined the growth inhibitory effect of anti-HER3
and MEHD7945A in BxPC3 cells. HRG-stimulated cells were
treatedwithanti-HER3,pertuzumab,cetuximab,orMEHD7945A.
As expected, treatment with anti-HER3 had a strong antiprolifer-
ative effect (IC50 = 1.10 mg/ml), whereas pertuzumab only slightly
inhibited growth and cetuximab was not effective under these
conditions (Figure 5B). MEHD7945A was superior to all other
treatments and inhibited growth of BxPC3 cells with an IC50 value
of 0.01 mg/ml.
To test MEHD7945A activity in vivo, BxPC3 cells were injected
subcutaneously into C.B-17 SCID mice and established tumors
were treated once a week with MEHD7945A, pertuzumab,
cetuximab, or anti-HER3. Because of its shorter half-life, we
adjusted the dosing of anti-HER3 to achieve an exposure similar
to the other antibodies. MEHD7945A inhibited tumor growth by
67% compared with vehicle control (Figure 5C). Anti-HER3
suppressed tumor growth by 37%, whereas pertuzumab and
cetuximab had only marginal effects. Tumor lysates were
collected 24 hr posttreatment and we verified that MEHD7945A
markedly decreased the phosphorylation of HER3 (Figure 5C).
To further investigate and compare the potency of MEHD7945A
and anti-HER3, we considered a patient-derived human breast
cancer transplant model, MAXF449. Established tumors were
treated once a week with MEHD7945A, pertuzumab, cetuximab,
anti-HER3, or the combination of cetuximab plus anti-HER3.
MEHD7945A and anti-HER3 significantly suppressed tumor
growth by 87% and 86%, respectively, whereas cetuximab
had no effect (Figure 5D).CMEHD7945A Shows Increased Activity in Xenografts
Relative to the Respective Monospecific Antibodies
Wenext investigated the effect ofMEHD7945A on EGFR-depen-
dent tumor growth using the NSCLCmodel NCI-H292. Complete
tumor regression was seen in both dose groups of MEHD7945A
(6.25 and 12.5 mg/kg) and in the 12.5 mg/kg cetuximab control
group suggesting that the dual-specific antibody was as effec-
tive as cetuximab. The anti-HER3 antibody, as expected, did
not have a statistically significant effect despite administration
of a high dose (Figure 6A). Tumor lysates were collected 24 hr
posttreatment and we verified that MEHD7945A markedly
decreased the phosphorylation of EGFR and the downstream
molecules phospho-ERK1/2 and phospho-S6 ribosomal protein
(Figure 6A).
Next, we determined the activity of MEHD7945A relative to
monospecific antibodies in additional xenografts where both
EGFR and HER3 signaling contribute to tumor growth. The
tumor growth of Calu-3 xenografts (NSCLC) was inhibited by
cetuximab (tumor growth inhibition: TGI 17%) or the anti-HER3
antibody (TGI 33%), while the combined blockade of EGFR-
and HER3-mediated signaling by MEHD7945A was most effec-
tive in inhibiting tumor growth (TGI 56%) (Figure 6B). A similar
antitumor effect was seen when cetuximab and anti-HER3
were given in combination (TGI 56%). Greater activity of
MEHD7945A compared with monospecific antibodies was also
seen in the FaDu (head and neck squamous cell carcinoma)
xenograft model. Interestingly, anti-HER3 and MEHD7945A
were equally potent during the course of antibody treatment,
whereas pertuzumab had no effect. However, the effect of
MEHD7945A was more sustained posttreatment compared
with anti-HER3 or cetuximab treatment (Figure 6C). Table S5
summarizes the in vivo potency of MEHD7945A compared with
monospecific antibodies in numerous murine xenograft models.
Collectively, MEHD7945A had equal activity to a monospecific
EGFR antibody when tumor growth is dependent on EGFR and
similar to a monospecific HER3 antibody when tumor growth de-
pended on HER3 activation. However, when both receptors
contributed to tumor growth MEHD7945A showed superior effi-
cacy over monospecific antibodies. These results confirm our
hypothesis that blocking more than one HER receptor pair
(EGFR homo/heterodimers and HER3/HER2 heterodimers)
substantially increases efficacy in HER-dependent tumors.
MEHD7945A Enhances Gemcitabine-Mediated
Cytotoxicity In Vitro and In Vivo
We investigated whether the combination of MEHD7945A and
gemcitabine, a chemotherapeutic agent commonly used in
NSCLC, would enhance the inhibition of cell proliferation of
MEHD7945A sensitive cell lines. NCI-H292, NCI-H1666, H358,
and HCC827 were treated with MEHD7945A plus gemcitabine
over a wide range of drug concentrations. Cell growth data
were analyzed using CalcuSyn software (Chou and Talalay,
1984). The resulting combination index (C.I.) values were <1
for most of the effective range of the drugs (fractional effect
0.2–0.8), demonstrating that the combination inhibited prolifera-
tion synergistically in these cell lines (Figure 6D).
We further evaluated combination treatment of gemcitabine
and MEHD7945A in vivo. NCI-H1975 tumors were treated with
gemcitabine (100 mg/kg biweekly), a moderately efficaciousancer Cell 20, 472–486, October 18, 2011 ª2011 Elsevier Inc. 479
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Figure 5. BxPC3 Cells and Xenografts Are Dependent on HER3 Signaling
(A) Knockdown of HER3 or EGFR by siRNA changes growth rate of BxPC3. Data presented as percentage of control cell growth. Error bars represent ± SD.
Detection of HER3 or EGFR levels after siRNA treatment in BxPC3 cells by immunoblotting.
(B) BxPC3 cells were treated with indicated concentrations of anti-HER3 (blue), MEHD7945A (red), pertuzumab (purple), or cetuximab (orange) and cell prolif-
eration was analyzed after 4 days by AlamarBlue staining.
(C) BxPC3 tumor-bearingmice were treated weekly using pertuzumab (25mg/kg, purple line), cetuximab (25mg/kg, orange line), anti-HER3 (50mg/kg, blue line),
MEHD7945A (25 mg/kg, red line), or vehicle (black line). First dose was given as a 23 loading dose. Arrows indicate treatments and data are presented as mean
tumor volume ± SEM. Percent tumor growth inhibition (TGI) was evaluated at Day 28. Tumor lysates of vehicle or MEHD7945A (25 mg/kg) treated tumors were
generated 24 hr posttreatment and phosphoHER3 status analyzed by immunoblotting.
(D) MAXF449 tumor-bearing mice were weekly injected intravenously with cetuximab (30 mg/kg, orange line), anti-HER3 (60 mg/kg, blue line), MEHD7945A
(30 mg/kg, red line), vehicle (black line), or intraperitoneally with pertuzumab (30 mg/kg, purple line). First dose was given as a 23 loading dose. Arrows indicate
treatments and data are presented as mean tumor volume ± SEM. Percent tumor growth inhibition (TGI) was evaluated at Day 25.
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Cancer Cell
Targeting HER3 and EGFR with a Two-in-One Antibodydose of MEHD7945A (2 mg/kg, weekly) or the combination
thereof. Adding a chemotherapeutic agent to the dual-specific
antibody resulted in strong tumor regression, whereas single
agents led to only delayed tumor growth (Figure 6E).
MEHD7945A Mediates Antibody-Dependent
Cell-Mediated Cytotoxicity
Clinical and preclinical data frommonoclonal antibodies such as
rituximab and trastuzumab (Junttila et al., 2010; Robak, 2009)
indicate that antibody-dependent cell-mediated cytotoxicity
(ADCC) contributes to their activities. In vitro and in vivo studies
imply that ADCC is at least partly involved in the antitumor
activity of cetuximab (Taylor et al., 2009). We therefore sought
to determine if MEHD7945A induces ADCC in vitro. A431 cells
were incubated with freshly isolated human peripheral blood
mononuclear cells (PBMCs) in the presence of MEHD7945A,
cetuximab, anti-HER3, or control antibody. MEHD7945A as
well as cetuximab mediated strong cytolytic activity, whereas
anti-HER3 or control antibody did not (Figure 7A).
To investigate thecontributionofADCCto the invitroand invivo
activity of MEHD7945A, we introduced the previously char-
acterized N297A mutation into the Fc domain of MEHD7945A
(Presta, 2006). ADCC is triggered when an antibody binds to its
antigen on a target cell and via its Fc region engages Fcg recep-
tors that are expressed on immune effector cells. The N297A
mutation severely compromises the antibody’s ability to recruit
immune effector cells. Indeed, MEHD7945A_N297A (designated
MEHD_N297A) was unable to induce ADCC of NCI-H292 cells,
whereas MEHD7945A provided a strong ADCC response (Fig-
ure 7B). The N297A mutation did not affect the antiproliferative
activity of the antibody. MEHD_N297A was as potent as
MEHD7945A in inhibiting cell growth in vitro (data not shown).
We next examined if ADCC also played a significant role in
the efficacy of MEHD7945A in vivo. We used the NCI-H292
EGFR-dependent xenograft model to compare the efficacy
of MEHD7945A and its variant MEHD_N297A. Interestingly,
both antibodies showed comparable activity through day 7 sug-
gesting that treatment with either antibody led to reduced tumor
volume by blocking the EGFR signaling pathway. However,
when antibody concentrations lessened over time MEHD7945A
sustained its in vivo potency for a much longer period than did
MEHD_N297A (Figure 7C). Since antibody exposure levels
were equal (data not shown), we attributed the difference in
potency to the fact that MEHD7945A was able to engage
immune effector cells but MEHD_N297A was not. A similar
dual mode of action involving inhibition of signaling and ADCC
was recently described for other anti-EGFR antibodies (Bleeker
et al., 2004; Schneider-Merck et al., 2010).
MEHD7945A Administration to Cynomolgus Monkeys
Results in Reduced Skin Toxicity Compared
with Cetuximab
In a majority of patients, the administration of EGFR antagonists
causes dermatologic toxicity that can become severe enough to
requiredose reductionordrugdiscontinuation (Li andPerez-Soler,
2009). To investigate if simultaneous inhibition of HER3 influences
this adverse event,wecompared the relativedermatologic toxicity
of MEHD7945A to cetuximab. Female cynomolgus monkeys
(three/group) were administered either cetuximab (25 mg/kgCweekly) or MEHD7945A (at 25 mg/kg or 12.5 mg/kg weekly) intra-
venously for 5 weeks. As summarized in Table 1 and consistent
with prior reports, dermatologic toxicity was observed between
the third and fourth doses in all three cetuximab-treated animals
(available at http://www.accessdata.fda.gov/drugsatfda_docs/
bla/2004/125084_ERBITUX_PHARMR_P1.PDF). In contrast, only
one of three animals given MEHD7945A at 25 mg/kg had
evidence of dermatologic toxicity. Notably, the skin lesions were
of lesser extent and severity, compared with the skin lesions in
animals given cetuximab, and appeared only after the sixth
dose. No animals treated with 12.5 mg/kg of MEHD7945A had
any gross evidence of dermatologic toxicity. Pharmocokinetic
analysis confirmed comparable exposure between treatment
groups dosed with cetuximab and MEHD7945A at 25 mg/kg
(data not shown); thus, the reduced relative toxicity was not due
to differential drug exposure. These data demonstrate that the
dermatologic toxicity of MEHD7945A is substantially less than
that of cetuximab and suggests that MEHD7945A may have
a superior clinical safety profile in comparison to established
EGFR antagonists.DISCUSSION
Herein, we provide evidence that MEHD7945A is capable of
binding two EGFR, two HER3, or one EGFR and one HER3 at
the same time. Different from bispecific agents with two distinct
monospecific binding functions, the presence of two identical
Fab arms in MEHD7945A raises the possibility that for a given
receptor density, any combination of EGFR and HER3 levels
should be recognized with near-equivalent avidity.
We demonstrated the advantage of dual blockade to inhibit
diverse intracellular signals in a number of in vitro systems and
we showed significant tumor growth inhibition in 12 xenograft
models that represent six different types of solid tumors. Interest-
ingly, MEHD7945A is more active than the prototypical EGFR
antibody, cetuximab, in four models, more active than our
HER3 antibody in five models, and is equivalently efficacious
as cetuximab or our HER3 antibody in the remaining three
models. Other investigators have recently reported on the identi-
fication, characterization, and initial clinical assessment of
specific HER3 antibodies. To date, the most extensively charac-
terized HER3 antibody is MM-121 (Schoeberl et al., 2010).
Notably, MM-121 is engineered as an IgG2, which is not ex-
pected to efficiently bind to FcgRIIIa on human immune effector
cells (Gessner et al., 1998). As such, MM-121 will not mediate
antibody-dependent cell-mediated cytotoxicity (ADCC). In con-
trast, we show both in vitro and in vivo that MEHD7945A, as an
IgG1, is highly effective in facilitating ADCC. Because MM-121
was not available for direct comparison, we tested MEHD7945A
in the A549 NSCLC model that has also been studied with
MM-121. A549 tumors were sensitive to anti-HER3 therapy
with both our dual-specific and monospecific HER3-directed
agents. Interestingly, similar efficacy was achieved with
MEHD7945A dosed at 100 mg/kg for 3 weeks as when
MM-121 was dosed at 210 mg/kg for 3 weeks (Schoeberl et al.,
2009). We acknowledge the limitations of this comparison.
Nevertheless, it is plausible that the increased potency observed
with MEHD7945A is due to slower clearance, targeting of bothancer Cell 20, 472–486, October 18, 2011 ª2011 Elsevier Inc. 481
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Figure 6. MEHD7945A Inhibits Tumor Growth in Xenograft Models and Shows Increased Inhibition When Combined with Gemcitabine
(A) Mice with established NCI-H292 xenografts were injected intraperitoneally with single dose of anti-HER3 (100 mg/kg, blue line), cetuximab (12.5 mg/kg,
orange line), MEHD7945A (6.25 mg/kg, red line), MEHD7945A (12.5 mg/kg, red dashed line), or vehicle (black line). Data are presented as mean tumor volume ±
SEM. Tumor lysates from vehicle or MEHD7945A (single dose, 50 mg/kg) treated tumors were generated 24 hr posttreatment and analyzed for phospho EGFR
using a pTyr antibody, pERK1/2 (Thr202/Tyr204), p-S6 ribosomal protein (pRP-S6; Ser235/236), EGFR, and tubulin.
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Figure 7. ADCC Contributes to the Antitumor Efficacy of MEHD7945A
(A) EGFR amplified A431 cells with normal expression of HER3 were incubated with freshly isolated PBMCs at a ratio of 1:25 and indicated concentrations of
cetuximab, MEHD7945A, anti-HER3, or control antibody. Antibody-dependent cytotoxicity was determined by measuring lactate dehydrogenase (LDH) release
in the supernatant.
(B) NCI-H292 cells and freshly isolated PBMCs (1:25 ratio) were incubated with indicated concentrations of MEHD7945A or MEHD7945A_N297A (in figure
abbreviated to MEHD_N297A), and LDH release was determined in the supernatant.
(C) NCI-H292-bearing mice were treated with a single dose ofMEHD7945A (6.25mg/kg, red line), MEHD7945A_N297A (6.25mg/kg, purple line), or vehicle (black
line), and data are presented as mean tumor volume ± SEM.
Cancer Cell
Targeting HER3 and EGFR with a Two-in-One AntibodyHER3 and EGFR, engagement of immune effector functions, or
a combination of some or all of these attributes.
We hypothesized that given HER3’s ability to potently couple
to the PI3 kinase pathway, antagonizing HER signaling with our
dual-targeted agent in the presence of chemotherapy may
broadly potentiate cytotoxicity. Our initial investigations suggest
that the cytotoxicity of gemcitabine is strongly augmented by(B) Calu-3-bearing mice were treated weekly with cetuximab (25 mg/kg, orange li
line), the combination of weekly cetuximab + biweekly anti-HER3 (25 mg/kg each
Arrows indicate treatments and data are presented as mean tumor volume ± SE
(C) FaDu tumor-bearing mice were treated weekly with cetuximab (25 mg/kg, oran
anti-HER3 (50mg/kg, blue line), or vehicle (black line). First dose was given as a 23
dosing and data are presented as mean tumor volume ± SEM
(D) Cell proliferation of NCI-H292, H1666, H358, and HCC827 cells was determin
index (C.I.) values were determined using CalcuSyn software. For drug combina
eration) C.I. values <1 indicate drug synergy.
(E) NCI-H1975-bearing mice were treated weekly with MEHD7945A (2 mg/kg, re
weekly MEHD7945A+ biweekly gemcitabine (brown line) or vehicle (black line). Cr
presented as mean tumor volume ± SEM. Percent TGI was evaluated at Day 25.
CMEHD7945A (Figure 6). Significantly greater in vivo activity
was seen in the NCI-1975 NSCLC model, whose EGFR harbors
both an activating mutation (L858R) and the erlotinib/gefitinib
resistance mutation (T790M). These data are particularly
intriguing since large clinical trials of chemotherapy in combina-
tion with erlotinib or gefitinib in lung cancer were unsuccessful
(Giaccone, 2004; Herbst et al., 2005).ne), MEHD7945A (25 mg/kg, red line), biweekly with anti-HER3 (25 mg/kg, blue
), gray line), or vehicle (black line). First dose was given as a 23 loading dose.
M. Percent TGI was evaluated at Day 24.
ge line), pertuzumab (25 mg/kg, purple line), MEHD7945A (25 mg/kg, red line),
loading dose. Cross bars indicate euthanized animals. Arrows indicate days of
ed after 5 days of treatment with MEHD7945A and gemcitabine. Combination
tions with fractional effect between 0.2 and 0.8 (inhibiting 20%–80% of prolif-
d line), biweekly with gemcitabine (100 mg/kg, blue line), the combination of
oss bars indicate euthanized animals. Arrows indicate treatments and data are
See also Table S5.
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Table 1. Preclinical Toxicology Results fromNonhumanPrimates
Test Articlea Dose (mg/kg)b
Dermatological Findings
Time to Onset
(Study Day)
Extent and
Severity
Cetuximab 25 16, 19, 22c Mild to Severed
MEHD7945A 25 43, NA, NA Mild to Moderate
MEHD7945A 12.5 NA, NA, NA NA
NA, not applicable.
a Cynomolgus monkeys (n = 3/group) were given cetuximab or
MEHD7945A weekly for 5 weeks (total of six doses) followed by a
4 week recovery period.
b Drug exposure was comparable for cetuximab and MEHD7945A given
at 25 mg/kg throughout the study period.
c Time to onset of dermatologic lesions is comparable to those previously
reported for cetuximab (available at http://www.accessdata.fda.gov/
drugsatfda_docs/bla/2004/125084_ERBITUX_PHARMR_P1.PDF).
d Dermatological lesions remained throughout drug administration phase
and resolved by the end of the 4 week drug-free recovery period (Study
Day 63).
Cancer Cell
Targeting HER3 and EGFR with a Two-in-One AntibodyUnexpectedly, our nonhuman primate studies revealed that
MEHD7945A exhibits far less skin toxicity in comparison to ce-
tuximab. Evidently, simultaneous blockade of HER3 and EGFR
signaling does not worsen the well-known skin liability of estab-
lished EGFR antagonists and appears to decrease their derma-
tologic toxicity. The mechanistic explanation for this observation
is currently under investigation. One plausible hypothesis is that
heregulin-HER3 signaling in the skin is a stress response to
EGFR antagonism. Naturally, confirmation of this observation
awaits validation in human subjects.
In contrast to EGFR or HER2, no prevalent genetic alterations
are reported for HER3. As a result, cancer patients whose tumors
are driven by HER3 activation may be difficult to identify due to
technical complexities in analyzing pathway activation in archival
tumor tissue. Here, we demonstrated that TGF-a predominantly
activated the MAPK pathway in both normal and EGFR-ampli-
fied cells, whereas HRG stimulation of HER3 primarily activated
the PI3K/AKT pathway, and only blockade of both EGFR and
HER3 signaling completely ablated activation of both pathways
under ligand-rich conditions. These data are in agreement with
clinical observations of strong downmodulation of MAPK sig-
naling but not AKT signaling in skin and tumor biopsies of
patients treated with anti-EGFR agents (Folprecht et al., 2008;
Tabernero et al., 2010). Recent diagnostic studies underscore
the interplay of EGFR, HER3, and their ligands in HNSCC (Hick-
inson et al., 2009).
Sensitivity to aparticular anticancer agent evolvesduring treat-
ment (Engelman and Settleman, 2008; Wheeler et al., 2008). It is
plausible that simultaneously targeting of more than one prolifer-
ation and survival signal, or targeting a resistance mechanism,
will provide better clinical outcomes. The interdependence of
HER/ErbB receptors may underlie acquired resistance to EGFR
or HER2 targeted agents. A variety of compensatory mecha-
nisms are postulated: upregulation of ligands for HER3 or
EGFR (Kong et al., 2008; Yonesaka et al., 2011; Zhou et al.,
2006), switching dimerization partners (Jain et al., 2010), or over-
expression of receptors, especially HER3 (Campbell et al., 2010;
Ritter et al., 2007). Because HER3 activation and/or expression484 Cancer Cell 20, 472–486, October 18, 2011 ª2011 Elsevier Inc.are identified as an evolved response to current anti-HER/ErbB
agents, early and direct blockade of HER3 signaling may delay
drug resistance. Recent data in support of this hypothesis
were obtained in a genetically engineered mouse model of lung
cancer demonstrating that cetuximab treatment results in the up-
regulation of HER3 phosphorylation and HRG expression and
combined treatment with cetuximab and the HER3 antibody
MM-121 delays resistance (Schoeberl et al., 2010).
Taken together, there is accumulating evidence to support the
hypothesis that simultaneously targeting more than one prolifer-
ation and survival signal, or targeting a resistance mechanism,
will provide better clinical outcomes. The unique potential of
MEHD7945A to both treat EGFR/HER3-driven disease and delay
HER3-dependent drug resistance warrants its consideration as
a promising anticancer therapy in the clinic.
EXPERIMENTAL PROCEDURES
Phage Library Construction and Selection
Phage-displayed Fab libraries with randomized heavy-chain CDRs were con-
structed as previously described with modestly modified degenerate oligonu-
cleotides (Lee et al., 2004). To select EGFR binding clones, the libraries were
subjected to four selection rounds on the immobilized target (EGFR-ECD-Fc).
Random clones were screened for EGFR-specific binders using ELISA (Lee
et al., 2004). The relative binding affinity was determined by competitive phage
ELISA. In short, purified phage clones that gave a 50%–70% saturating signal
were incubated with increasing concentrations of antigen (hEGFR-ECD) for
1 hour and unbound phage was captured in antigen-coated ELISA wells and
detected using an anti-phage antibody. EC50 was calculated as the concentra-
tion of antigen in solution that inhibited 50% of the phage from binding to im-
mobilized antigen. To recruit a second binding specificity into D1.5, selected
light-chain CDRs of D1.5 Fab displayed on phage were mutated (Bostrom
et al., 2009). The libraries were subjected to four rounds of binding selection
for HER3 and screening as described for the heavy-chain libraries. Clones
that bound HER3 in addition to EGFR were identified and expressed as Fab
and IgG for further characterization.
Crystallization, Structure Determination, and Refinement
DL11 was produced in Escherichia coli. The HER3 ECD domains 1-3 (Ser1-
His513) and EGFR ECD domain 3 (Arg310-Lys514) with C-terminal histidine
affinity tags (-GNSHis6) were each produced in baculovirus-infected insect
cells. DL11 alone and its complexes with HER3 and EGFR fragments were
subjected to crystallization trials in sitting drops. The sequence of DL11
differs from that of DL11f in only three places (Figure 2A). Detailed information
from protein production, crystallization, and structure solution appears in
Supplemental Material, including data reduction and refinement statistics in
Table S3.
In Vivo Drug Efficacy
For xenograft studies, naive SCID beige or C.B-17 SCID mice (Charles River
Laboratories, San Diego or Hollister, CA) were inoculated subcutaneously
with Calu3, NCI-H292, BxPC3, NCI-H1975, or FaDu cells. Mice with similarly
sized tumors (mean volume 150–350 mm3) were randomized into treatment
cohorts and treatments were administered intraperitoneally. Single-dose
studies consisted of a single treatment on the day of randomization.
Multiple-dose studies consisted of 4 weeks of treatment, with the first dose
(day of randomization) being a 23 loading dose. Tumors were measured
with calipers at least once a week. Studies were reviewed and approved by
the Institutional Animal Care and Use Committee (IACUC) at Genentech. The
MAXF449 xenograft model was established at Oncotest GmbH from primary
patient material after informed consent of the patient and approval by the
Ethics Board at the University of Freiburg. The mouse efficacy experiment
was reviewed and approved by the Regierungs pra¨sidium Freiburg, Germany,
and conducted according to the guidelines of the German Animal Welfare Act.
Xenografts were subcutaneously grown in athymic NMRI nu/nu mice and
Cancer Cell
Targeting HER3 and EGFR with a Two-in-One Antibodyrandomized after reaching tumor volumes of 100 mm3. Mice were treated with
antibodies once aweek intravenously with the exception of pertuzumab, which
was administered intraperitoneally. Antibodies were dosed for 4 consecutive
weeks with the first dose (day of randomization) being a 23 loading dose.
Toxicity Study in Cynomolgus Monkeys
Nine experimentally naive female cynomolgus monkeys (Macaca fascicularis)
were randomly assigned to dosing groups (n = 3/group). Cetuximab (Capital
Wholesale Drug Company) was not diluted prior to dose administration
and used at the supplied concentration. Dilutions of MEHD7945A to 5 or
2.5 mg/ml were performed on each dosing day. Cetuximab (Group 1;
25mg/kg) or MEHD7945A (Groups 2 and 3; 25mg/kg and 12.5mg/kg, respec-
tively) was administered via slow pump infusion once weekly for six doses over
5 consecutive weeks (Days 1, 8, 15, 22, 29, and 36). Cage-side observations
were performed once daily during acclimation and twice daily beginning on
Day 1. Each animal was observed for overall health, including evidence of
dermatologic toxicity. All animals were housed, maintained, and treated in
accordance to standard ethical animal handling guidelines. The study was
reviewed and approved by the Institutional Animal Care and Use Committee
(IACUC) at Valley Biosystems.ACCESSION NUMBERS
Final refined coordinates and structure factors for DL11 alone and its
complexes with EGFR and HER3 have been deposited at the Protein Data
Bank under accession codes 3P0V, 3P0Y, and 3P11, respectively.
Supplemental Material
Supplemental Material includes Experimental Procedures, references, three
figures, and five tables and can be found online at doi:10.1016/j.ccr.2011.
09.003.
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